Notes
incremental cost-effectiveness ratio
Reference
Kongnakorn T, et al. Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis . Internet Document : 4 Apr 2014. Available from: URL: http://dx.doi.org/10.2147/CEOR.S55095
Rights and permissions
About this article
Cite this article
Bendamustine beats competitors in CLL. PharmacoEcon Outcomes News 700, 4 (2014). https://doi.org/10.1007/s40274-014-1163-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1163-x